(Total Views: 360)
Posted On: 04/17/2018 7:13:14 PM
Post# of 15624
Re: Mistafixit #12937
Good point about the sublingual soluble tablet. The following had never been reported before:
It further goes on to say:
Compared to last year's 10-K I thought this one was much more comprehensive and detailed. As an observation it was also twice as long...173 pages vs. 84. But let's face it they are equally boring and the sort of thing that you want to read if you're trying to fall asleep.
Quote:
On August 1, 2017 we entered into a service agreement with PharmItBe Ltd (“PharmItBe”) for the development process of the second generation of our cannabis soluble tablet delivery system and preparing the tablet for clinical trials.
It further goes on to say:
Quote:
On December 20, 2017, we announced that we received a new permit from the Israel Medical Cannabis Agency (“IMCA”) to proceed with the safety study of our cannabis soluble tablet delivery system. The study protocol has been submitted and approved by the Institutional Review Board (“IRB”) at Tel Aviv Sourasky Medical Center (“Sourasky”) and has been approved by them. We are now waiting for the approval by the central Israeli Review Board. The study is scheduled to start in the second fiscal quarter of 2018.
Compared to last year's 10-K I thought this one was much more comprehensive and detailed. As an observation it was also twice as long...173 pages vs. 84. But let's face it they are equally boring and the sort of thing that you want to read if you're trying to fall asleep.
(3)
(0)
